+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are exploring the effects of kombucha, a fermented tea beverage, on individuals who are overweight or have class 1 obesity. This study aims to understand how kombucha, including its live microbiota, influences metabolic factors like glucose, insulin, and lipid levels, as well as gut microbiota diversity and liver function. The trial is a randomized controlled pilot study assessing these impacts through clinical and biological measures. Participants are randomly assigned to one of three groups one group drinks 33 cl of live kombucha daily, another drinks 33 cl of pasteurized kombucha daily, and a third group drinks 33 cl of sparkling water as a control. Each intervention lasts for 4 weeks, and the study includes dietary supplementation with the assigned beverage. The trial involves a triple-blind design to reduce bias. During the study, participants undergo assessments of their gut microbiota through fecal samples, fasting glucose and insulin levels, insulin resistance, lipid profiles, liver enzymes, and biomarkers of oxidative stress and inflammation. Questionnaires about gastrointestinal symptoms and stool consistency are also completed. The trial aims to measure changes over the 4-week period to evaluate kombuchas potential effects on metabolism, microbiota, and liver health.

Age: 18Years - 60YearsAll GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Researchers are investigating how a sleep behavioral intervention combined with standard obesity treatment affects adolescents aged 13 to 17 who have overweight or obesity with poor sleep quality. The study aims to better understand how improving sleep may help reduce body fat and improve related health risks like insulin resistance and hypertension. This trial compares usual obesity treatment alone to usual treatment plus a sleep-focused behavioral therapy delivered by psychologists. Participants will be randomly assigned to either the control group receiving standard obesity care or the intervention group receiving standard care plus seven cognitive-behavioral therapy sessions over six months. These sessions focus on improving sleep hygiene, self-monitoring, stimulus control, cognitive therapy, and relaxation techniques. Medical visits occur every two months during the six-month intervention and every three months during a six-month follow-up period. During the study, participants will undergo assessments including body measurements BMI, waist circumference, fat mass, sleep evaluations using actigraphy and ambulatory sleep studies, blood tests for metabolic markers, and questionnaires on sleep, eating habits, physical activity, emotional well-being, and quality of life. The primary outcome is changes in BMI z-score and body composition at six months. Secondary outcomes include cardiometabolic risk factors, hormonal levels, and emotional measures, with safety and progress monitored throughout the 12-month study period.

Age: 13Years - 17YearsAll GendersPhase Not Applicable
2 locations
R

Actively Recruiting

Researchers are evaluating whether EP-088MM09, which contains modified house dust mite allergens called mannan-conjugated allergoids, can treat house dust mite allergy. This Phase 3 clinical trial involves 250 participants aged 12 to 65 years with persistent moderate to severe nasal allergy symptoms, with or without eye symptoms, and possibly mild or moderate controlled allergic asthma. The study aims to compare the treatments effect on allergy symptoms and the need for relief medicines against a placebo while assessing safety. Participants will be randomly assigned to receive either EP-088MM09 or a placebo, both given as subcutaneous injections. The treatment phase includes 12 monthly visits where participants receive injections under the skin the first visit involves two injections, and subsequent visits involve one injection each. Some participants sensitive to pollen may have an additional baseline visit to ensure symptom assessments avoid pollen season influence. After completing treatment, a final follow-up visit occurs about one month later. Throughout the study, participants will attend screening visits to confirm eligibility, complete daily symptom and medication diaries during specified periods, and provide blood samples and questionnaires on symptoms and quality of life. Clinic visits include monitoring of health and medication use, with participants staying at the clinic for at least 30 minutes after each injection. The main outcome measured is a combined score of symptoms and medication use over four weeks following treatment. Participation lasts approximately 14 to 21 months.

Age: 12Years - 65YearsAll GendersPhase 3
16 locations